BioMarin Pharmaceutical Q3 Earnings Call Highlights
BioMarin (BMRN) reported Q3 earnings, with Voxzogo revenue up 12% YoY to $245M. The company lowered 2026 revenue guidance to $3.8B-$3.9B due to order timing and regional disruptions. Non-GAAP EPS guidance is $2.80-$3.10, including impacts from recent acquisitions. BioMarin also provided updates on its pipeline, including BMN 450 for Fabry disease and BMN 440 for hypophosphatasia.
How this was made
The 30-second read
Why it matters
Guidance reduction is likely to trigger a sell‑off in BMRN, but pipeline developments may provide a longer‑term catalyst.
Market read
The earnings call delivers fresh guidance cuts and acquisition impact, making the news highly relevant for traders holding or shorting BMRN.
What to watch
Potential upside from upcoming hypochondroplasia launch and BMN 450 pipeline could mitigate earnings pressure.
Background
BioMarin reported Q3 results, highlighted product performance, and announced a lower full‑year guidance due to order timing and acquisition costs.
Ticker impact
BioMarin cut full-year 2026 revenue guidance to $3.8‑$3.9B and lowered non‑GAAP EPS to $2.80‑$3.10 after the Q3 earnings call.
likely downward pressure as investors price in lower revenue and EPS guidance
Guidance cuts are material and were first disclosed in this call; market typically reacts promptly.
Market effects
Rare‑disease biotech sector may see broader valuation pressure as guidance cuts highlight execution risk.
U.S. biotech indices could dip modestly following the news.
Limited to investors with exposure to BioMarin and similar rare‑disease companies.
Counterpoint
The order‑timing delay may be temporary; long‑term growth from international expansion could offset short‑term guidance cuts.
Key entities
- companyBioMarin Pharmaceutical Inc.
Biotech firm focused on rare diseases, ticker BMRN.
- companyAlesta Therapeutics
Acquired by BioMarin; acquisition costs drive EPS reduction.
